Скачать или смотреть Mabion Biologics CDMO Drives the Future of Antibody Development and Manufacturing

In biologics outsourcing, finding the right CDMO can feel like the Goldilocks dilemma. Just as Goldilocks sought what was "just right," antibody developers must balance capabilities and contracts to find the ideal CDMO for their needs. Join experts from Mabion as they share insights and best practices on selecting, qualifying, and managing CDMO partnerships.

Mabion aims to strengthen its position as a key player in the European biologics CDMO market. Our mission is to provide personalized manufacturing solutions for therapeutic proteins, including biosimilars and originator drugs, monoclonal antibodies, bispecifics and multispecific drugs.

For more informations write to us at bd@mabion.eu

🔎 You can find this webinar by searching:
Outsourcing Biologic Drug Development
Biologics Commercialization Outsourcing
Key Technologies for Biologicals CDMOs
Key Platforms for Biologicals CDMOs
Key Skills for Biologicals CDMOs
The Best Biologics CDMO
CDMO as a Strategic Advisor
Early Planning for Biologic Drug Scale-up
Building Successful CDMO Partnerships
The Best CDMO for Biologics

The webinar features:
Nigel Stapleton, VP of Business Development - Head of Europe at Mabion (as moderator)
Adam Pietruszkiewicz, Chief Commercial Officer of Mabion
Edyta Bartusik-Czubek, Development of Analytics Division Manager, Upstream and Downstream Process Development Division Manager at Mabion
Marta Bednarek, Marta Bednarek, Director of Manufacturing and Operations at Mabion
Anna Małecka, Regulatory and Scientific Affairs Division Manager at Mabion
Łukasz Waszak, Director of Quality Assurance at Mabion